The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study
Open accessAbstract
Background & Aims Chronic liver disease (CLD) represents a major global health burden. We undertook this study to identify the factors associated with adverse outcomes in patients with CLD who acquire the novel coronavirus-2019 (COVID-19). Methods We conducted a multi-center, observational cohort study across 21 institutions in the United States (US) of adult patients with CLD and laboratory-confirmed diagnosis of COVID-19 between March 1, 2020 and May 30, 2020. We performed survival analysis to identify independent predictors of all-cause mortality and COVID-19 related mortality, and multivariate logistic regression to determine the risk of severe COVID-19 in patients with CLD. Results Of the 978 patients in our cohort, 867 patients (mean age 56.9 ± 14.5 years, 55% male) met inclusion criteria. The overall all-cause mortality was 14.0% (n = 121), and 61.7% (n = 535) had severe COVID-19. Patients presenting with diarrhea or nausea/vomiting were more likely to have severe COVID-19. The liver-specific factors associated with independent risk of higher overall mortality were alcohol-related liver disease (ALD) (hazard ratio [HR] 2.42, 95% confidence interval [CI] 1.29–4.55), decompensated cirrhosis (HR 2.91 [1.70–5.00]) and hepatocellular carcinoma (HCC) (HR 3.31 [1.53–7.16]). Other factors were increasing age, diabetes, hypertension, chronic obstructive pulmonary disease and current smoker. Hispanic ethnicity (odds ratio [OR] 2.33 [1.47–3.70]) and decompensated cirrhosis (OR 2.50 [1.20–5.21]) were independently associated with risk for severe COVID-19. Conclusions The risk factors which predict higher overall mortality among patients with CLD and COVID-19 are ALD, decompensated cirrhosis and HCC. Hispanic ethnicity and decompensated cirrhosis are associated with severe COVID-19. Our results will enable risk stratification and personalization of the management of patients with CLD and COVID-19. Clinicaltrials.gov number NCT04439084
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Self-citationCancer patients in SARS-CoV-2 infection: a nationwide analysis in China
Liang, W., Guan, W., Chen, R., Wang, W., Li, J., Xu, K., Li, C., Ai, Q., Lu, W., Liang, H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30096-6 · Cited by 4,384 · cited 1×
“Patients with cancer, in general, have worse clinical outcomes after COVID-19.(14,25) Patients with HCC may be uniquely susceptible to COVID-19 related complications because of a constellation of active malignancy, presence of cirrhosis, as well as the presence of an active underlying liver disease that led to that ci…”
BackgroundClinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31187-9 · Cited by 1,726
Sepanlou, S. G., Safiri, S., Bisignano, C., Ikuta, K. S., Merat, S., Saberifiroozi, M., Poustchi, H., Tsoi, D., Colombara, D. V., Abdoli, A., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30349-8 · Cited by 1,714
Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance
Albillos, A., Lario, M., & Álvarez-Mon, M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.010 · Cited by 1,242 · cited 1×
“We posit the less favorable outcomes noted in patients with decompensated cirrhosis may be due to cirrhosis-associated immune dysfunction and fragile physiological buffers, likely increasing susceptibility to severe COVID-19.(18) Our findings highlight the challenges in taking extra precautions to minimize the risk of…”
Gut–Liver Axis in Alcoholic Liver Disease
Szabo, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.042 · Cited by 754
Determinants of alcohol use and abuse: Impact of quantity and frequency patterns on liver disease
Zakhari, S., & Li, T.-K. (2007) · Hepatology · doi:10.1002/hep.22010 · Cited by 333 · cited 1×
“Alcohol use was defined as no drinking, social drinking (2 drinks/day for men and up to 1 drink/day for women), or current daily drinking (drinking more than social drinking limits on a daily basis).(13) Data on decompensation were collected from chart review for clinical events.”
Cited by
COVID-19 and liver disease: mechanistic and clinical perspectives
Marjot, T., Webb, G. J., Barritt, A. S., Moon, A. M., Stamataki, Z., Wong, V. W., & Barnes, E. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00426-4 · Cited by 385
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Metadata
- Authors
- Kim, D., Adeniji, N., Latt, N., Kumar, S., Bloom, P. P., Aby, E. S., Perumalswami, P., Roytman, M., Li, M., Vogel, A. S., Catana, A. M., Wegermann, K., Carr, R. M., Aloman, C., Chen, V. L., Rabiee, A., Sadowski, B., Nguyen, V., Dunn, W., Chavin, K. D., Zhou, K., Lizaola-Mayo, B., Moghe, A., Debes, J., Lee, T.-H., Branch, A. D., Viveiros, K., Chan, W., Chascsa, D. M., Kwo, P., & Dhanasekaran, R.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 19
- Issue
- 7
- Pages
- 1469-1479.e19
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W3085849982
- Cited by
- 232
- References
- 7
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study. https://app.cochat.ai/papers/10.1016/j.cgh.2020.09.027
- The paper
- Kim, D., Adeniji, N., Latt, N., Kumar, S., Bloom, P. P., Aby, E. S., Perumalswami, P., Roytman, M., Li, M., Vogel, A. S., Catana, A. M., Wegermann, K., Carr, R. M., Aloman, C., Chen, V. L., Rabiee, A., Sadowski, B., Nguyen, V., Dunn, W., . . . Dhanasekaran, R. (2021). Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2020.09.027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.